retatrutide for diabetes Dialogue: Reduces Body Weight 28.7% in Phase 3 Trial Extreme Side Effects Followed Overdose

PMCID: PMC9960425

Set a realistic timeline Gradual and sustainable weight loss is best in any scenario, but especially during breastfeeding

J.et al (1996)

However, GLP-1 holding infinitesimal plasma half life limits its therapeutic effects

Weight Loss Results by Dose What this means: At the highest dose, nearly everyone (100%) lost at least 5% of their body weight, and 93% lost at least 15%

In laboratory studies, Retatrutide is investigated for its potential to modulate biological signaling through simultaneous engagement of three receptor pathways: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)